关键 词 | 资本事件 |力文所|Pre-A轮 【SynBioCon】 获 悉，AI蛋白质设计领域的领先企业 杭州力文所生物科技有限公司 （Levinthal Biotech，以下简称"力文所"） 宣布成功完成数千万人民币Pre-A轮融资。本轮融资由 金雨茂物 领 投， 君科丹木 跟投， 舟渡资本 担任独家财务顾问。 据悉，本轮资金将主要用于 加速其全原子模型蛋白质设计平台Pallatom的技术迭代、商业化产品管 线的拓展以及全球化人才的引进 。需要特别指出的是， Pallatom在全球首次解决了混旋性环肽设 计难题，为新一代环肽药物的管线开发开辟了新路径。 01 致敬莱文塔尔，以AI破解蛋白质设计悖论 力文所成立于2021年9月，是一家通过AI算法驱动进行蛋白质设计的科技型企业。公司 名"Levinthal Biotech"致敬了分子生物学先驱赛勒斯·莱文塔尔（Cyrus Levinthal）。他曾提出著 名的 "莱文塔尔悖论" ：如果一个蛋白质靠随机试错来寻找其正确结构，所需时间将远超宇宙年龄； 但在现实中，蛋白质却能在毫秒级的时间内完成折叠。 这一悖论启发了无数科学家去探索生命背后的理性设计规律。力文所 ...

Company Overview - Wuxi Tushen Zhihuo Artificial Intelligence Technology Co., Ltd. (Tushen Zhihuo) completed a multi-million RMB angel round financing, with participation from Shanghai Angel Association and continued investment from existing shareholder Chengmei Capital [1][3] - Founded in December 2023, Tushen Zhihuo focuses on AI-driven protein design in the biotechnology sector, leveraging advanced AI technology for high-value protein and related product development [2][3] - The company is led by Wang Yuguang, an associate professor at Shanghai Jiao Tong University, with a strong background in AI, applied mathematics, and synthetic biology [2][3] Technology and Innovation - Tushen Zhihuo has developed a scientific intelligence platform for the biopharmaceutical field, enabling automated antibody design and protein expression testing [2][3] - The company has achieved significant advancements in industrial applications, such as improving the affinity of rabbit monoclonal antibodies beyond that of leading European pharmaceutical companies and enhancing enzyme activity by 380% and 800% for specific enzymes [3] Funding and Investment - Tushen Zhihuo has completed four rounds of financing within two years, indicating strong investor confidence and interest in the AI protein design sector [3][5] - Chengmei Capital has been a consistent investor, recognizing the potential of AI technology across various industries and the team's solid technical background [3][5] Industry Landscape - The global protein design market is rapidly evolving, with a focus on the application of AI in drug development, industrial enzyme catalysis, and biomanufacturing [4][5] - Approximately 30 AI protein-related companies are based in China, while 25 are located overseas, with most technologies originating from academic institutions [5][6] - Chinese companies emphasize practical applications and industrial efficiency in AI protein design, contrasting with overseas firms that focus on foundational breakthroughs [6] Challenges and Future Outlook - The AI protein design sector faces challenges such as data quality, model interpretability, and high costs of wet lab validation, which are critical for transitioning from research to commercial applications [6]